DCX and non-small cell lung carcinoma: In the same study, renal cell or non-small cell lung carcinoma patients, whose tumors had high expression of DC-associated genes, responded better to treatment with atezolizumab (anti-PD-L1), where the treatment significantly improved overall survival compared to patients whose tumors had low expression of these genes [88].